A new study published in The Journal of Neuroscience shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain, which will reduce pathology of Alzheimer’s disease (AD) and protect memory.
Kalipada Pahan, professor of neurological sciences, biochemistry and pharmacology in Rush Medical College, and colleagues demonstrated that aspirin decreases amyloid plaque pathology in mice by stimulating lysosomes — the component of animal cells that help clear cellular debris.
“The results of our study identifies a possible new role for one of the most widely used, common, over-the-counter medications in the world,” said Dr. Pahan.
Alzheimer’s disease is a fatal form of dementia that affects up to 1 in 10 Americans age 65 or older. To date, the FDA has approved very few drugs for the treatment of Alzheimer’s disease-related dementia and the medications that exist can only provide limited symptomatic relief. The exact cause of the disease’s progression is unknown; however, poor disposal of the toxic protein amyloid beta in the brain is a leading mechanism in memory loss and dementia.
Activating the cellular machinery responsible for removing waste from the brain, therefore, has emerged as a promising strategy for slowing Alzheimer’s disease.
Amyloid beta forms clumps called amyloid plaques, which harm connections between nerve cells and are one of the major signs of Alzheimer’s disease. Building on previous studies demonstrating a link between aspirin and reduced risk and prevalence of Alzheimer’s disease,
Lysosomes play a central role in cellular homeostasis by regulating the cellular degradative machinery. Since aberrant lysosomal function has been associated with multiple lysosomal storage and neurodegenerative disorders, enhancement of lysosomal clearance has emerged as an attractive therapeutic strategy.
“Understanding how plaques are cleared is important to developing effective drugs that stop the progression of Alzheimer’s disease,” said Pahan.
A protein called Transcription factor EB (TFEB) is considered the master regulator of waste removal. The researchers gave aspirin orally for a month to genetically modified mice with Alzheimer’s pathology, then evaluated the amount of amyloid plaque in the parts of the brain affected most by the disease.
They found that the aspirin medications augmented TFEB, stimulated lysosomes and decreased amyloid plaque pathology in the mice.
“This research study adds another potential benefit to aspirin’s already established uses for pain relief and for the treatment of cardiovascular diseases,” said Pahan. “More research needs to be completed, but the findings of our study has major potential implications for the therapeutic use of aspirin in AD and other dementia-related illnesses.”
For further reference log on to https://doi.org/10.1523/JNEUROSCI.0054-18.2018